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Background: There is a deep need to improve the care of metastatic breast cancer (MBC) 
patients, since even today it remains an incurable disease. Taxanes are considered the most 
effective cytotoxic drugs for the treatment of MBC, both in monotherapy and in combined 
schedules, but the need for synthetic solvents contributes to the severe toxicities and may have 
a negative impact on the efficacy. Nanoparticle albumin-bound paclitaxel (Nab-paclitaxel) is 
a colloidal suspension of paclitaxel and human serum albumin initially developed to avoid the 
toxicities associated with conventional taxanes.
Patients and methods: The aim of this prospective, single-center open-label, noncomparative 
study was to evaluate the efficacy and safety of nab-paclitaxel in MBC patients pretreated with 
taxanes. The patients were treated with nab-paclitaxel as a single agent, 260 mg/m2 on day 1 of 
each 3-week cycle or 125 mg/m2 weekly. The primary endpoint was the overall response rate 
(ORR). Secondary objectives were duration of response, clinical benefit rate, progression-free 
survival (PFS), overall survival, and safety.
Results: A total of 42 patients (median age 48 years, median Eastern Cooperative Oncology 
Group performance status 0, triple-negative MBC 19%, all pretreated with a taxane-based 
therapy, mainly in advanced disease) were enrolled in the study. The ORR was 23.8%, including 
one complete response (2.4%) and nine partial responses (21.4%); the disease control rate was 
50%. The median duration of response was 7.2 months. After a median follow-up of 9 months, 
the median PFS was 4.6 months. ORR and PFS were similar irrespective of the previous chemo-
therapy lines, metastatic sites, and biomolecular expression. Nab-paclitaxel was well tolerated, 
and the most frequent treatment-related toxicities were mild to moderate (grades 1–2).
Conclusion: This real-life study shows that nab-paclitaxel has a significant antitumor activity 
and a manageable safety profile in patients pretreated with taxanes and experiencing a treatment 
failure after at least one line of chemotherapy.
Keywords: nab-paclitaxel, metastatic breast cancer, anthracyclines
Introduction
There is a deep need to improve the care of metastatic breast cancer (MBC) patients, 
since today, despite the output of new drugs in the therapeutic landscape, it remains 
an incurable disease. The therapeutic objectives are palliative, mainly in controlling 
symptoms, improving/maintaining quality of life, and prolonging survival, and care-
fully balancing the efficacy and toxicity of the treatment.1,2
Currently, taxanes (paclitaxel and docetaxel) are considered the most effective 
cytotoxic drugs for the treatment of MBC, both in monotherapy and in combined 
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schedules,3 and drugs of choice, according to the most 
recent international guidelines.1,4 Despite the well-known 
clinical activity of taxanes against most tumors, it has been 
demonstrated that the need for synthetic solvents (because of 
drugs’ hydrophobicity) contributes to the severe toxicities, 
such as hypersensitivity reactions and peripheral neuropa-
thy. In addition, these solvents may have a negative impact 
on efficacy due to an entrapment of active drug in plasma 
micelles, leading to increased systemic drug exposure, 
decreased drug clearance, nonlinear pharmacokinetics, and 
lack of dose-dependent antitumor activity.5,6
Nanoparticle albumin-bound paclitaxel (Nab-paclitaxel) 
is a colloidal suspension of paclitaxel and human serum 
albumin initially developed to avoid the toxicities associated 
with solvents. This drug utilizes the natural properties of 
albumin: the physiological transport of lipophilic molecules 
in bloodstream and a preferential deliver paclitaxel to tumors 
by biologically interacting with albumin receptors that medi-
ate drug transport.7 Nab-paclitaxel allows the safe infusion 
of significantly higher doses of paclitaxel than the doses 
used with standard paclitaxel therapy, with shorter infusion 
schedules (30 minutes vs 3 hours, respectively) and no 
premedication.5 Nab-paclitaxel was developed to improve the 
already known antitumor activity of conventional paclitaxel 
in terms of increased efficacy and better tolerability.
Several pivotal trials evaluated the efficacy and safety 
of nab-paclitaxel in the treatment of MBC patients, even in 
heavily pretreated, taxane-refractory women, both at the dose 
of 260 mg/m2 as a three-weekly (q3w) regimen and 150 mg/
m2 weekly. These studies showed that nab-paclitaxel was 
superior to the other conventional taxanes in terms of overall 
response rate (ORR) and progression-free survival (PFS), with 
a favorable toxicity profile.5,8–11 Additional studies demon-
strated that nab-paclitaxel is also active against more aggres-
sive forms of MBC, such as triple-negative tumors.12,13
The objective of this study was to analyze the efficacy and 
toxicity of nab-paclitaxel in taxane-pretreated MBC patients 
in a real-world setting and to define its activity according to 
the clinical characteristics and biological features.
Patients and methods
study setting and design
The aim of this prospective, single center open-label, non-
comparative study was to evaluate the efficacy and safety 
of nab-paclitaxel in MBC patients pretreated with taxanes. 
All data were stored in a centralized database and analyzed 
at the Regina Elena National Cancer Institute in Rome. 
During treatment, all adverse events related to the treatment 
were recorded on the electronic case report form. The study 
was conducted according to the Declaration of Helsinki; all 
patients provided a written informed consent before undergo-
ing any study-specific procedure.
The primary endpoint was the ORR, defined as the rate 
of patients with a complete response (CR) or partial response 
(PR). Secondary objectives were duration of response, 
clinical benefit rate (CBR), PFS, overall survival (OS), 
and safety.
Treatment activity was assessed every 12 weeks accord-
ing to Response Evaluation Criteria in Solid Tumor criteria.14 
Overall response was defined as the best confirmed response 
in each patient from the date of enrollment until the end of the 
study. Response duration was calculated from the start of the 
treatment to the first evidence of disease progression, and CBR 
was defined as the proportion of patients with CR, PR, or stable 
disease (SD) lasting $6 months. CR and PR were confirmed 
after 4 weeks from the last assessment by computed tomogra-
phy scan. PFS was defined as the time period ranging from the 
enrollment to the first documented progression and OS the time 
period between study enrollment and date of death. In case of 
brain metastasis, a magnetic resonance imaging was performed 
every 12 weeks. Patients who received at least one dose of study 
drug were considered evaluable for safety analysis.
Toxicity was assessed every 3 weeks or weekly accor-
ding to the used schedule and to the National Cancer 
Institute Common Terminology Criteria for Adverse Events 
(Version 4.02). Toxicity was evaluated through clinical 
evaluation, complete blood cell count, and full serum 
chemistry and graded according to the National Common 
Toxicity Criteria.
Patient population
All patients ($18 years) previously treated with taxanes in the 
adjuvant or metastatic setting were consecutively enrolled in 
the study. The eligibility criteria were histological diagnosis 
of invasive breast cancer, presence of metastatic disease, 
and previous treatment with at least one chemotherapy for 
advanced disease. Patients should have an Eastern Coop-
erative Oncology Group performance status 2 and a life 
expectancy of $3 months. Patients with previously controlled 
neoplastic disease within 5 years before study entry were 
considered for inclusion. Patients with asymptomatic central 
nervous system metastases were eligible, and treatment with 
surgery or radiation therapy of brain lesions should have been 
performed no .3 months before study entry. Patients with a 
grade .2 of peripheral neuropathy due to previous neurotoxic 
drugs were excluded from the study treatment. An absolute 
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neutrophil count .1,500/mL, platelet count .100,000/mL, 
bilirubin ,2 mg/dL, aspartato amino-transferase (AST)/
alanina amino-transferase (ALT) ,2 times the upper normal 
limit, and creatinine ,1.5 mg/dL were required. Pregnancy and 
breastfeeding were conditions for exclusion. Other concomi-
tant anticancer therapies were not admitted, and radiotherapy 
to extracranial sites or hormonal therapy should terminate at 
least 1 month before starting nab-paclitaxel treatment.
schedule of treatment
All the enrolled patients were treated with nab-paclitaxel as a 
single agent, at the dose of 260 mg/m2 as a 30-minute intrave-
nous infusion on day 1 of each 3-week cycle or 125 mg/m2 as 
a 30-minute intravenous infusion weekly. Each vial contains 
100 mg of paclitaxel (as paclitaxel albumin). After reconstitu-
tion, each milliliter of suspension contains 5 mg of paclitaxel 
(as paclitaxel albumin). The reconstituted medicinal product 
contains ~425 mg sodium per dose.
The drug was administered on an outpatient basis without 
steroid or antihistamine premedication, specialized intrave-
nous infusion sets, or inline filtration.
The treatment was administered until documented disease 
progression, unacceptable toxicity, or refusal of the patient. 
The choice of schedule was at the discretion of the investiga-
tor taking into account the age of the patient, performance 
status, and burden of disease.
Grade 3 or 4 toxic effects were managed by dose modi-
fications. Concomitant treatments that did not interfere with 
the evaluation of nab-paclitaxel, including the use of bispho-
sphonates, could be given at the investigator’s discretion.
histopathological analysis
Histopathological information was directly documented 
from the original pathology reports. Tumor histotype, grad-
ing, expression of estrogen receptors (ER) and progesterone 
receptors (PgR), proliferation index as assessed by Ki-67 
staining, and human epidermal receptor (HER)-2 status were 
evaluated on formalin-fixed, paraffin-embedded tumor tissue. 
Immunostainings for ER, PgR, and HER-2 were performed 
using the monoclonal antibodies 6F11 and 1A6 (Novocastra, 
Menarini, Florence, Italy) and the polyclonal antibody A0485 
(Dako Denmark A/S, Glostrup, Denmark). Immunoreactions 
were revealed by a streptavidin–biotin enhanced immunoper-
oxidase technique (Super Sensitive MultiLink, Menarini) 
in an automated autostainer (Menarini). Diaminobenzidine 
was used as the chromogenic substrate. The tumors were 
considered to be positive for ER and PgR if $5% of the 
cells showed positive staining. The cutoff point for Ki-67 
status was regarded as .14% positively stained cells. HER-2 
status was given in the pathology reports as 0, 1+, 2+, or 3+ 
scores. Tumors with a score of 0 or 1+ were regarded as 
HER-2-negative, and those with a score of 3+ were regarded 
as HER-2-positive. Tumors with a 2+ staining were tested for 
gene amplification by silver in situ hybridization (Hoffman-La 
Roche Ltd., Basel, Switzerland) or fluorescence in situ hybrid-
ization (Dako Denmark A/S). The molecular breast cancer 
subtypes were approximated taking into account ER, PgR, 
HER-2 status, and, when available, Ki67 proliferation index 
of the primary tumor. Patients were categorized as follows: 
luminal A (ER and/or PgR positive and HER-2 negative), 
luminal B-like (ER and/or PgR positive, HER-2 positive, 
Ki67 14%, or HER-2 negative with high Ki67 .14), HER-
2-subtype (ER and PgR negative and HER-2 positive), and 
triple negative (ER, PgR, and HER-2 negative).
statistical analysis
This prospective observational study planned an accrual of 
a total of 42 patients in order to estimate an ORR of ~15% 
with a standard error of 5%.
Data were summarized using descriptive statistics, abso-
lute frequencies, and percentages when considering categori-
cal variables and median and range when quantitative. The 
Kaplan–Meier method was used to estimate median time and 
survival rates for PFS and OS. IBM-SPSS Version 20 was 
used for all statistical analyses.
Results
A total of 42 patients were enrolled in this study. Table 1 
shows their clinical characteristics. The median age was 
48 years (range: 21–80 years); most of the patients were in 
postmenopausal status; median Eastern Cooperative Oncol-
ogy Group performance status was 0 (range: 0–2). Eight 
patients (19%) had a triple-negative MBC.
All patients received a prior taxane-based therapy, mainly 
in the advanced disease (66.7%). In particular, five patients 
had been administered a taxane-including regimen, either in 
the adjuvant or the metastatic setting. The median time elapsed 
from the previous taxane-containing adjuvant or metastatic 
treatment was 43 months (12–178 months) and 28 months 
(11–46 months), respectively. Previous anthracyclines were 
administered to 85.8% of the patients. All patients had 
previously received at least one first-line treatment for the 
metastatic disease (in ~12% . four lines), and 80% of them 
had received also a previous hormonal therapy. The median 
number of metastatic sites was three (range: 1–4), a visceral 
involvement being present in ~78.5% of cases.
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Table 1 Demographic and clinical characteristics of patients
Total number of patients 42
Median age (years, range) 48 (21–80)
ecOg performance status (median, %)
0 25 (59.5%)
1 15 (35.7%)
2 2 (4.8%)
histologic subtypes (n, %)
luminal a 10 (23.8%)
luminal B-like her2− 19 (45.2%)
luminal B-like her2+ 3 (7.1%)
her2 like 2 (4.8%)
Triple negative 8 (19%)
Previous taxanes (n, %) 42 (100%)
adjuvant setting 19a (45.2%)
Metastatic setting 28 (66.7%)
Median time to previous taxanes (months, range)
adjuvant 43 (12–178)
Metastatic 28 (11–46)
Previous anthracyclines (n, %) 36 (85.8%)
adjuvant setting 20 (47.7%)
Metastatic setting 16 (38%)
not done 6 (14.3%)
Previous chemotherapy lines (n, %)
1 7 (16.7%)
2 15 (35.7%)
3 15 (35.7%)
.4 5 (11.9%)
Previous hormonal therapy (n, %) 32 (80%)
Median number of metastatic sites (range) 3 (1–4)
Dominant metastatic site (n, %)
liver 23 (54.7%)
lung 10 (23.8%)
Bone 4 (9.5%)
soft tissues 5 (11.9%)
Nab-paclitaxel schedule (n, %)
3-weekly 10 (23.8%)
Weekly 32 (76.2%)
Note: aFive patients received taxane-including regimens both in adjuvant and in 
metastatic setting.
Abbreviations: her2, human epidermal receptor 2; Nab, nanoparticle albumin 
bound; ecOg, eastern cooperative Oncol ogy group.
Ten patients (23.8%) were given the 3-weekly schedule of 
nab-paclitaxel and 32 (76.2%) with weekly administration.
Efficacy
After a median number of six cycles (range: 1–11) (a total 
of 450 weekly administration given to patients), the ORR 
was 23.8%, including one CR (2.4%) and nine PR (21.4%). 
A disease stabilization was obtained in eleven cases (26.2%), 
for a disease control rate (DCR) of 50% (Table 2). In the 
group of patients (total ten) who had 3-weekly schedule, 
only one patient achieved PR and four and five patients 
showed stability and progression of disease, respectively. 
The median duration of response was 7.2 months (95% 
 confidence  interval: 6.7–8.7 months). Among the ten patients 
who received the 3-weekly schedule, one PR and four stabil-
ity of disease were observed.
Table 2 clinical response (global population: 42 patients)
Clinical response Number (%)
complete response 1 (2.4)
Partial response 9 (21.4)
Orr 10 (23.8) (95% ci [12.1–39.5])
stable disease 11 (26.2)
Disease control rate 21 (50) (95% ci [34.2–65.8])
Disease progression 21 (50)
Abbreviations: ORR, overall response rate; CI, confidence interval.
The clinical response was also evaluated according to 
the previous chemotherapy lines (Table 3) and metastatic 
sites (Table 4). Among seven patients who received one 
previous line for metastatic disease, four (57%) and two 
(28.5%) partial responses and stable disease were observed, 
respectively; a total of 15 patients received two previous 
metastatic lines, one (7%) and three (20%) patients achieved 
complete and partial responses, respectively, and six (40%) 
patients showed stability of disease. Among women given 
three lines of chemotherapy (n=15), one PR (7%), two SD 
(13%), and 12 progression of disease (80%) were registered, 
while in those treated with four lines (n=5), one PR (20%) 
was documented. No difference was observed between the 
groups (P=0.83). It is noteworthy that the best response is 
reached using nab-paclitaxel in the early lines of chemo-
therapy (second or third line). Response by site was shown in 
Table 4; in particular, a DCR of 60% and 54%, respectively, 
in lung and liver sites was observed.
After a median follow-up of 9 months (range: 2–38 months), 
the median PFS was 4.6 months (95% confidence 
interval: 2.7–6.8, range: 5–21+). Because a small cohort 
of patients was treated with 3-weekly schedule, no comparison 
between the two regimens in terms of efficacy was done.
Table 5 shows PFS according to previously adminis-
tered chemotherapy. The median PFS in patients receiving 
up to two lines was 4.6 months, while it was 3.0 months 
in those receiving more than four lines of chemotherapy 
(P=0.89). The median PFS in patients with less than two 
or with two more than two metastatic sites was 5.7 months 
and 3.7 months, respectively (P=0.35). The median PFS in 
Table 3 clinical response, n (%), according to previous chemo-
therapy lines
Clinical response One line  
(n=7)
Two lines  
(n=15)
Three lines  
(n=15)
Four lines 
(n=5)
complete response 0 1 (7) 0 0
Partial response 4 (57) 3 (20) 1 (7) 1 (20)
stable disease 2 (28.5) 6 (40) 2 (13) 1 (20)
Disease progression 1 (14) 5 (33) 12 (80) 3 (60)
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Table 4 clinical response according to different metastatic sites
Site N Number (%)
CR PR SD PD
lung 15 – 1 (7) 8 (53) 6 (40)
liver 24 – 5 (21) 8 (33) 11 (46)
Bone 12 – 9 (75) – 3 (25)
soft tissues 10 1 (10) 3 (30) 5 (50) 1 (10)
Brain 8 – – 6 (75) 2 (25)
Abbreviations: cr, complete response; Pr, partial response; sD, stable disease; 
PD, progression disease.
Table 5 Progression-free survival according to previous chemo-
therapy lines, number of metastatic sites, and kind of metastasis
Progression-free  
survival (months)
P-value
,2 lines 5.4 (3.4–7.4) 0.89
.2 lines 4.5 (1.4–7.5)
,2 metastatic sites 5.7 (2.8–8.5) 0.35
.2 metastatic sites 3.7 (1.2–6.2)
Visceral metastasis 4.7 (1.5–7.9) 0.43
no visceral metastasis 4.6 (2.0–7.2)
patients with only visceral metastases versus those without 
visceral metastases was 4.7 months and 4.6 months, respec-
tively. All these differences were not statistically significant. 
Finally, the OS rate at 1 year was 53.8%.
Efficacy in accordance with biomolecular 
expression
In Tables 6 and 7 are shown results regarding efficacy accord-
ing to biomolecular expression of all patients. The response 
rate and DCR were slightly higher in luminal A tumors 
(30% and 60%, respectively) than luminal B HER2-negative 
tumors (26% and 53%, respectively). A positive result was 
also observed in more aggressive breast cancer, such as 
triple-negative tumors (response rate 25% and DCR 50%). By 
contrast, the positivity of HER2 reduced the clinical efficacy 
induced by nab-paclitaxel (0% and 33%, respectively). The 
PFS was longer in triple-negative tumors (5.7 months) than 
in the other histotypes of MBC.
safety
All the enrolled patients were assessable for safety analysis. 
The most frequent treatment-related toxicities were mild to 
moderate (grades 1–2). Neutropenia was the main grade 3/4 
toxicity (70%), followed by leukopenia (25%), fatigue (13%), 
and peripheral neuropathy (12%) (Figure 1). Hematologi-
cal toxicity was similar among patients who received both 
weekly and 3-weekly schedule; higher incidence of grade 2 
peripheral neuropathy was documented in patients treated 
Table 6 Efficacy in accordance with biomolecular expression – 
activity
Histotypes Number  
of patients
Response  
rate (n, %)
Stable disease  
(n, %)
DCR  
(n, %)
luminal a 10 3 (30%) 3 (30%) 6 (60%)
luminal B
her2+ 3 0 1 (33%) 1 (33%)
her2− 19 5 (26%) 5 (26%) 10 (53%)
her2 like 2 0 0 0
Triple negative 8 2 (25%) 2 (25%) 4 (50%)
Total 42 10 (23.8%) 11 (26.2%) 21 (50%)
Abbreviations: Dcr, disease control rate; her2, human epidermal receptor 2.
Table 7 Progression-free survival
Histotypes Number of  
patients
Median PFS  
(months, 95% CI)
luminal a 10 5.4 (1.7–9.1)
luminal B
her2+ 3 3.0 (0.8–5.3)
her2− 19 4.7 (4.2–5.2)
her2 like 2 ne
Triple negative 8 5.7 (1.4–9.9)
Abbreviations: PFS, progression-free survival; CI, confidence interval; HER2, 
human epidermal receptor 2; ne, not evaluable.
with weekly nab-paclitaxel (28% vs 12%), and grade 3 was 
observed only in the weekly regimen.
Discussion
Taxanes have been widely demonstrated to be among the 
most active cytotoxic drugs for the treatment of breast cancer 
and, since their advent, provided a novel chemotherapy 
option in the treatment of patients with MBC. The novel 
solvent-free formulation of paclitaxel, nab-paclitaxel, has 
demonstrated a good safety and an efficacy profile compared 
with other taxanes, but no strong data to date are available 
about its role in taxane-pretreated MBC patients.
To our knowledge, this is the first study reporting the 
efficacy of nab-paclitaxel in patients submitted to previ-
ous taxanes treatment, either in the adjuvant (33%) or in 
the metastatic setting (67%). Our results showed a global 
ORR in about a quarter and a DCR in a half of these highly 
compromised patients, regardless of the number of previous 
chemotherapy lines received. In the study by Blum et al10 
taxane failure was defined as metastatic disease progression 
during taxane therapy or relapse within 12 months of adjuvant 
taxane therapy. These authors reported median PFS times of 
3 months at 100 mg/m2 and 3.5 months at 125 mg/m2 and 
median survival times of 9.2 months and 9.1 months, respec-
tively. By contrast, in our series, the median time elapsed 
from the previous taxane-containing adjuvant or metastatic 
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Figure 1 Main toxicity per patient observed in all study population. Both regimens (3-weekly [ten patients] and weekly [32 patients]) were cumulated in the figure.
Abbreviations: neutro, neutropenia; leuko, leukopenia; neur, neuropathy.
treatment was 43 months (range: 12–178) and 28 months 
(range: 11–46), respectively. This fact could explain the 
quite longer PFS (4.6 months) and extremely longer OS 
(26 months) reported in our study.
Considering other experiences reported in the literature, 
our real-life results resemble those reported in the literature. 
In particular, in the Phase II and III studies evaluating nab-
paclitaxel in monotherapy in the first-line treatment of patients 
with pretreated MBC, ORR ranged from 16% to 34%, PFS 
ranged from 3.0 months to 6.6 months, and OS ranged from 
9 months to 16.3 months.5,10,11 Although a better activity in 
patients treated with weekly schedule has been observed, we 
should not make an analysis comparing the two schedules for 
the different sample sizes between the two regimens. This is 
also the first study to demonstrate the activity of nab-paclitaxel 
in certain subtypes of patients, according to different 
metastatic sites. Furthermore, after a median follow-up of 
9 months, the median PFS was 4.6 months; a similar value 
was observed in all the analyzed subgroups, regardless of the 
number of previous lines or metastatic sites.
It is interesting to note the activity of the drugs in all 
subtypes (Tables 6 and 7). It is noteworthy that the median 
PFS observed in the triple-negative population, which notori-
ously shows a poorer prognosis, resembled that registered in 
the luminal A group. As previously reported, nab-paclitaxel 
is also active against more aggressive forms of MBC, such 
as triple-negative tumors.12,13 Probably when disease is in an 
advanced phase of evolution, as in our cohort of patients, and 
when patients are heavily pretreated, the value of biological 
features could be lost, and it is possible to note not a so deep 
difference in terms of results between the biological subtypes 
with the use of cytotoxic drugs.
The toxicity profile observed in our cohort is quite similar 
to that of other studies in pretreated patients, but with some dif-
ferences. Neutropenia was the main grade 3/4 toxicity observed 
in our study (70%), which is slightly higher than that reported 
by Ibrahim et al11 (grade 4 neutropenia in 24% of patients, 
primarily during the first treatment cycle and managed with 
dose reduction, and grade 3 neutropenia in 27% of patients), 
but much higher than that reported in other two studies on 
pretreated patients (30% and 34%, respectively).5,10 The rate 
of grade 3/4 leukopenia (25%) was lower than that reported by 
Blum et al10 (36%) but much higher than that of pivotal study on 
nab-paclitaxel.5 Grade 3/4 peripheral neuropathy rate was 12% 
in our cohort, the same was observed by Ibrahim et al11 (11%) 
and Gradishar et al5 (10%), in both cases easily managed and 
improved rapidly to grade 1/2. On the contrary, in the 125 mg/m2 
cohort of the Blum study, 14 patients (19%) developed grade 
3 sensory neuropathy, three of whom had preexisting grade 1 
peripheral neuropathy. These patients typically could be 
restarted on a reduced dose of albumin-bound paclitaxel after 
a 1- to 2-week delay.10 No new toxicity was detected in real-life 
management with nab-paclitaxel of patients with pretreated 
MBC. We reported higher incidence of neuropathy in patients 
who were submitted to weekly administration of the drug 
(125 mg/mq/w) (grade 2, 28%; grade 3, 12%). These data are 
likely to be referred to the higher dose-intensity administered 
drug in patients already treated with taxanes.
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A very recent prospective, multicenter study assessed the 
activity, safety, and quality of life of nab-paclitaxel 260 mg/m2 
q3w as second-line chemotherapy in 52 HER2-negative, 
taxane-pretreated MBC patients enrolled in three Italian 
centers. The ORR was 48%, including 13.5% of CR, and the 
overall CBR was 77%. The median PFS was 8.9 months. 
The main grade 3/4 toxicities observed in this study were 
leukopenia in 25% of patients, neutropenia in 21.2% of 
patients, and peripheral neuropathy in 5.8% of patients. The 
better activity and the lower rate of neutropenia and peripheral 
neuropathy reported by the authors were probably related to 
the use of this drug only in the second-line setting.15
Conclusion
In conclusion, this real-life study demonstrates that nab- 
paclitaxel, an innovative formulation of albumin-bound 
paclitaxel, has a significant antitumor activity and a man-
ageable safety profile in patients pretreated with taxanes 
and experiencing a treatment failure after at least one line 
of chemotherapy; this cytotoxic drug was demonstrated to 
be active also in more aggressive breast cancers, such as 
triple-negative tumors. Furthermore, nab-paclitaxel shows a 
number of advantages over existing taxanes, facilitating drug 
administration and improving patient acceptance, particularly 
due to the absence of premedication with corticosteroids or 
prolonged infusions or special intravenous infusion sets. 
The latter consideration is important in the general economy 
of care16 and the patient’s quality of life.
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